COVID-19 outcomes in patients taking cardioprotective medications
Fritha J Morrison, Maxwell Su, Alexander Turchin
PLOS ONE, doi:10.1371/journal.pone.0275787
Introduction The coronavirus disease 2019 (COVID-19) caused a worldwide pandemic and has led to over five million deaths. Many cardiovascular risk factors (e.g. obesity or diabetes) are associated with an increased risk of adverse outcomes in COVID-19. On the other hand, it has been suggested that medications used to treat cardiometabolic conditions may have protective effects for patients with COVID-19.
Objectives To determine whether patients taking four classes of cardioprotective medications-aspirin, metformin, renin angiotensin aldosterone system inhibitors (RAASi) and statins-have a lower risk of adverse outcomes of COVID-19.
Methods We conducted a retrospective cohort study of primary care patients at a large integrated healthcare delivery system who had a positive COVID-19 test between March 2020 and March 2021. We compared outcomes of patients who were taking one of the study medications at the time of the COVID-19 test to patients who took a medication from the same class in the past (to minimize bias by indication). The following outcomes were compared: a) hospitalization; b) ICU admission; c) intubation; and d) death. Multivariable analysis was used to adjust for patient demographics and comorbidities.
Results Among 13,585 study patients, 1,970 (14.5%) were hospitalized; 763 (5.6%) were admitted to an ICU; 373 (2.8%) were intubated and 720 (5.3%) died. In bivariate analyses, patients taking metformin, RAASi and statins had lower risk of hospitalization, ICU admission and death. However, in multivariable analysis, only the lower risk of death remained statistically significant. Patients taking aspirin had a significantly higher risk of hospitalization in both bivariate and multivariable analyses.
Author Contributions Conceptualization: Alexander Turchin.
References
Alamdari, Afaghi, Rahimi, Tarki, Tavana et al., Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. The Tohoku journal of experimental medicine,
doi:10.1620/tjem.252.73Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate behavioral research,
doi:10.1080/00273171.2011.568786Bramante, Ingraham, Murray, Marmor, Hovertsen et al., Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19, medRxiv,
doi:10.1101/2020.06.19.20135095Cariou, Goronflot, Rimbert, Boullu, May et al., Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study, Diabetes & Metabolism,
doi:10.1016/j.diabet.2020.10.001Chen, Yang, Cheng, Chen, Peng et al., Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication, Diabetes Care,
doi:10.2337/dc20-0660Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019, Anesth Analg,
doi:10.1213/ANE.0000000000005292Crouse, Grimes, Li, Might, Ovalle et al., Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes, Front Endocrinol,
doi:10.3389/fendo.2020.600439Delgado, Baweja, Crews, Eneanya, Gadegbeku et al., A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease, Am J Kidney Dis,
doi:10.1053/j.ajkd.2021.08.003Do, Kim, Park, Cho, Kang, Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? Diabetes & metabolism,
doi:10.1016/j.diabet.2020.10.006Felice, Nardin, Tanna, Grossi, Bernardi et al., Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives, Am J Hypertens,
doi:10.1093/ajh/hpaa096Frohlich, Jeschke, Eichler, Thiele, Alhariri et al., Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany, Clin Res Cardiol,
doi:10.1007/s00392-020-01783-xGu, Xie, Li, Zhang, Lai et al., Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus, Sci Rep,
doi:10.1038/srep19840Gupta, Madhavan, Poterucha, Defilippis, Hennessey et al., Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19, Nat Commun,
doi:10.1038/s41467-021-21553-1Hergens, Bell, Haglund, Sundstrom, Lampa et al., Risk factors for COVID-19-related death, hospitalization and intensive care: a population-wide study of all inhabitants in Stockholm, Eur J Epidemiol,
doi:10.1007/s10654-021-00840-7Holman, Knighton, Kar, 'keefe, Curley et al., Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587%2820%2930271-0Inciardi, Solomon, Ridker, Metra, Coronavirus 2019 Disease (COVID-19), Systemic Inflammation, and Cardiovascular Disease, J Am Heart Assoc,
doi:10.1161/JAHA.120.017756Khunti, Knighton, Zaccardi, Bakhai, Barron et al., Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England,
doi:10.1016/S2213-8587%2821%2900050-4Kuba, Imai, Rao, Gao, Guo et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat Med,
doi:10.1038/nm1267Kuno, So, Iwagami, Takahashi, Egorova, The association of statins use with survival of patients with COVID-19, Journal of cardiology,
doi:10.1016/j.jjcc.2021.12.012Li, Ashcroft, Chung, Dighero, Dozier et al., Risk factors for poor outcomes in hospitalised COVID-19 patients: A systematic review and meta-analysis,
doi:10.7189/jogh.11.10001Mitacchione, Schiavone, Curnis, Arca, Antinori et al., Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy, Journal of clinical lipidology,
doi:10.1016/j.jacl.2020.12.008Moccia, Gerbino, Lionetti, Miragoli, Munaron et al., COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches, Geroscience,
doi:10.1007/s11357-020-00198-wNguyen, Ho, Nguyen, Ho, Li et al., Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis, Metabolism,
doi:10.1016/j.metabol.2022.155196Reynolds, Adhikari, Pulgarin, Troxel, Iturrate et al., Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2008975Saeed, Castagna, Agalliu, Xue, Patel et al., Statin Use and In-Hospital Mortality in Patients With Diabetes Mellitus and COVID-19, Journal of the American Heart Association,
doi:10.1161/JAHA.120.018475Seiglie, Platt, Cromer, Bunda, Foulkes et al., Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19, Diabetes Care,
doi:10.2337/dc20-1506Spiegeleer, Bronselaer, Teo, Byttebier, Tre et al., The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents, Journal of the American Medical Directors Association,
doi:10.1016/j.jamda.2020.06.018Vaduganathan, Vardeny, Michel, Mcmurray, Pfeffer et al., Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMsr2005760Valero, Civit, Dupont, Selnihhin, Reinert et al., A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2112942118Villa, Brunialti, Dellavedova, Meda, Rebecchi et al., DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic, Pharmacol Res,
doi:10.1016/j.phrs.2021.105982Wang, Van Oekelen, Mouhieddine, Valle, Richter et al., A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward, J Hematol Oncol,
doi:10.1186/s13045-020-00934-xYin, Wang, Song, Li, Miao, Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials, Am J Hypertens,
doi:10.1093/ajh/hpac001Zhang, Qin, Cheng, Shen, Zhao et al., In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19, Cell metabolism,
doi:10.1016/j.cmet.2020.06.015Zhang, Zhu, Cai, Lei, Qin et al., Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circulation research,
doi:10.1161/CIRCRESAHA.120.317134Zibaeenezhad, Lu, Zahra, Mahboobeh, Lionetti, Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure, Heart Fail Rev,
doi:10.1007/s10741-020-10016-2Zou, Yan, Shu, Gao, Sun et al., Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections, Nat Commun,
doi:10.1038/ncomms4594
